Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombotic microangiopathies.

Daniel Halevy1, Jai Radhakrishnan, Glen Markowitz

  • 1Division of Nephrology, Department of Medicine, Columbia-Presbyterian Medical Center, New York, NY, USA.

Critical Care Clinics
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.

American journal of hematology·2026
Same author

New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.

Kidney medicine·2026
Same author

Kidney International introduces new article type: Clinical Journey in Translational Medicine.

Kidney international·2026
Same author

Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.

JAMA network open·2026
Same author

Corrigendum to "New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases": [Kidney Medicine 7 (2025) 101133].

Kidney medicine·2026
Same author

Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy.

Glomerular diseases·2026
Same journal

Critical Care and Contagion: Evolving Frontiers of Infectious Diseases in the Modern Intensive Care Unit.

Critical care clinics·2026
Same journal

Advances and Challenges in Sepsis Care in Low-Resource Settings.

Critical care clinics·2026
Same journal

The Respiratory Triple Pandemic in the Intensive Care Unit: Epidemiology, Clinical Features and Management of COVID-19, Influenza and Respiratory Syncytial Virus.

Critical care clinics·2026
Same journal

Antibiotic Stewardship for the Intensivist.

Critical care clinics·2026
Same journal

Infection Prevention and Control in the Intensive Care Unit.

Critical care clinics·2026
Same journal

Antibiotic Considerations in the Critically Ill: Empiric Choices and Dosing.

Critical care clinics·2026
See all related articles

Thrombotic microangiopathies (TMA) are serious conditions causing red blood cell destruction, low platelets, and organ damage. These diseases stem from blood vessel injury and clot formation, with outcomes varying by underlying cause.

Area of Science:

  • Hematology
  • Pathology
  • Internal Medicine

Background:

  • Thrombotic microangiopathies (TMA) encompass a spectrum of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage.
  • A common pathogenic pathway involves endothelial cell injury and the formation of microvascular thrombi.

Purpose of the Study:

  • To summarize the key features and underlying mechanisms of thrombotic microangiopathies.
  • To highlight the importance of identifying the specific underlying disease for prognosis and treatment.

Main Methods:

  • Review of existing literature on thrombotic microangiopathies.
  • Analysis of common pathophysiological mechanisms across different TMA entities.
  • Synthesis of information regarding diagnostic and therapeutic approaches.

Related Experiment Videos

Main Results:

  • TMA share a common mechanism of endothelial injury and thrombus formation.
  • Clinical manifestations include hemolytic anemia, thrombocytopenia, and organ dysfunction.
  • Prognosis and treatment strategies are contingent upon the specific etiology of the TMA.

Conclusions:

  • Understanding the shared pathogenic basis of TMA is crucial for clinical management.
  • Tailored treatment based on the underlying cause is essential for improving patient outcomes in TMA.